Psoriatic Arthritis Market

Key Findings:

 

  • In 7MM, Psoriatic arthritis market size was approximately USD 9 billion in 2021.
  • Several companies are working robustly on many new therapies, such as bimekizumab (UCB Biopharma), tildrakizumab (Sun Pharmaceutical), deucravacitinib (BMS), and izokibep (Affibody AB).
  • The total prevalent patient population of psoriatic arthritis (PsA) in the 7MM countries was close to 15 million in 2021.

 

Request a sample to unlock the CAGR for Psoriatic arthritis Market.

 

DelveInsight’s ‘Psoriatic Arthritis (PsA) – Market Insights, Epidemiology, and Market Forecast – 2032’ report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of psoriatic arthritis (PsA) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

Psoriatic arthritis (PsA) market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted psoriatic arthritis (PsA) market size from 2019–2032 segmented by 7MM. The report also covers the current psoriatic arthritis (PsA) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study period: 2019–2032

Psoriatic Arthritis (PsA): Disease Understanding and Treatment Algorithm

Psoriatic Arthritis (PsA) Overview

Psoriatic arthritis (PsA) is a form of arthritis associated with psoriasis, chronic skin and nail disease characterized by red, scaly rashes and thick pitted fingernails. Psoriatic arthritis (PsA) resembles rheumatoid arthritis (RA) in symptoms characterized by joint inflammation. However, psoriatic arthritis (PsA) affects fewer joints than RA and does not produce the typical RA antibodies.

 

In 1956, Wright described arthritis associated with psoriasis. However, it was not until 1973 that Moll and Wright defined the various clinical phenotypes, including axial PsA, symmetrical polyarthritis, asymmetrical oligoarthritis, distal interphalangeal (DIP) arthritis, and arthritis mutilans. The following year, these authors introduced the concept of spondyloarthritis, a cluster of diseases with shared clinical and immunogenetic features. Despite these advances, the immunopathogenesis of psoriatic arthritis (PsA) remained poorly understood, awaiting a more detailed understanding of immune networks and the inflammatory response.

 

The etiology and pathogenesis of psoriatic arthritis (PsA) involve a complex interaction between genetic and environmental factors resulting in immune-mediated inflammation involving the skin and joints and may involve other organs. Approximately 33–50% of psoriatic arthritis (PsA) patients have at least one first-degree relative with psoriasis or psoriatic arthritis (PsA). Genes associated with psoriatic arthritis (PsA) include those in the HLA region involved in antigen presentation and immune recognition and non-HLA genes involved in immune activation and inflammation, including intracellular signaling, cytokine expression, signaling, and T-cell effector function. The role of environmental factors is suspected but has been difficult to confirm. Skin trauma induces psoriatic skin lesions flares, known as the Koebner phenomenon. Evidence suggests that joint trauma may cause a flare of arthritis, referred to as the “internal” or “deep” Koebner phenomenon.

 

Psoriatic arthritis (PsA) shares some clinical features with other inflammatory arthritides, including RA, reactive arthritis (ReA), and ankylosing spondylitis (AS). In some cases, it is difficult to make a precise diagnosis. Unlike psoriatic arthritis (PsA), RA is symmetrical and generally spares the DIP joints. AS has an earlier onset age than psoriatic arthritis (PsA), and sacroiliac involvement is usually symmetric rather than asymmetric.

 

Psoriatic arthritis (PsA) may range from mild to severe, and treating it no matter the severity is crucial. If left untreated, psoriatic arthritis (PsA) can cause permanent joint damage, which may be disabling. In addition to preventing irreversible joint damage, treating psoriatic arthritis (PsA) may also help reduce inflammation that could lead to other comorbidities. However, no cure for psoriatic arthritis (PsA) exists, so treatment goals are to slow disease progression, improve QoL, lessen pain, and preserve the range of motion. In most psoriatic arthritis (PsA) patients, pharmacological treatment consists of a trial-and-error approach, beginning with corticosteroids and nonsteroidal anti-inflammatory drugs to manage symptoms. Physicians often use conventional synthetic disease-modifying antirheumatic drugs (DMARDs), followed by biological DMARDs, if a patient does not respond adequately.

 

Psoriatic Arthritis Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the psoriatic arthritis (PsA) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

Psoriatic Arthritis Epidemiology

Psoriatic arthritis (PsA) epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of KOL. The report also provides the prevalent patient pool, trends, and assumptions.

 

Psoriatic Arthritis Key Findings

The disease epidemiology covered in the report provides historical and forecasted psoriatic arthritis (PsA) epidemiology segmented as the prevalent cases of psoriatic arthritis (PsA), diagnosed cases of psoriatic arthritis (PsA), gender-specific cases of psoriatic arthritis (PsA), age-specific cases of psoriatic arthritis (PsA) and severity-specific cases of psoriatic arthritis (PsA). The report includes the prevalent psoriatic arthritis (PsA) scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

 

‘Psoriatic Arthritis Prevalence

 

Country-wise Psoriatic Arthritis Epidemiology

The epidemiology segment also provides psoriatic arthritis (PsA) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The total prevalent patient population of psoriatic arthritis (PsA) in the 7MM countries was close to 15 million in 2021.

 

As per the estimates, the US had the highest total prevalent patient population of psoriatic arthritis (PsA) population in 2021. Among the EU5 countries, Spain had the highest total prevalent patient population of psoriatic arthritis (PsA), with more than 200,000 cases, followed by Italy in 2021. On the other hand, France had the lowest total prevalent patient population of psoriatic arthritis (PsA), close to 53,000 cases in 2021.

Psoriatic Arthritis Drug Chapters

The drug chapter segment of psoriatic arthritis (PsA) report encloses the detailed analysis of psoriatic arthritis (PsA) marketed drugs and late-stage (Phase III, Phase II/III, Phase II, and Phase I/II) pipeline drugs. It also helps understand psoriatic arthritis (PsA) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

The current standard of care lacks efficiency in treating psoriatic arthritis (PsA) that permanently cures PsA and demands need to develop more effective therapies for PsA. Although many effective PsA therapies, including csDMARDS, TNF inhibitors, various anti-IL inhibitors, and a variety of small molecule therapeutics, have been introduced over the last decade, spanning several different mechanisms of action. Still, many patients often do not respond to treatment due to various resistance symptoms. In addition to this, concerns over long-term safety profiles of csDMARDS and currently available biologics may limit their use, and patients can find treatments difficult due to regular blood monitoring, concerns of side effects, method of administration as well as the impact on metabolic risk, which in turn can lead to poor compliance and dissatisfaction.

Products detail in the report…

 

Psoriatic Arthritis Emerging Drugs

Drug developers are gradually shifting their attention toward psoriatic arthritis (PsA) to meet the patient pool’s current demands and counter the unmet needs of the therapeutic market.

 

Several Psoriatic Arthritis companies are working robustly on many new therapies, such as bimekizumab (UCB Biopharma), tildrakizumab (Sun Pharmaceutical), deucravacitinib (BMS), and izokibep (Affibody AB).

 

Bimekizumab (UCB Biopharma) is an investigational, humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F, two key cytokines driving inflammatory processes. IL-17F has overlapping biology with IL-17A and drives inflammation independently of IL-17A.

 

The safety and efficacy of bimekizumab are being evaluated across multiple disease states as part of a robust clinical program. The company is evaluating the drug in multiple Phase III clinical studies for PsA.

 

Tildrakizumab (Sun Pharmaceutical) is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of IL-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMYA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in the US.

 

The drug is currently being evaluated in Phase III clinical studies in subjects with active psoriatic arthritis (PsA) with prior exposure to an anti-TNF agent(s) as well as in anti-TNF naïve subjects with active psoriatic arthritis (PsA).

 

The company has filled marketing application for the manufacturing and marketing authorization of tildrakizumab for moderate-to-severe psoriasis and psoriatic arthritis (PsA) in Japan.

Products detail in the report…

 

Psoriatic Arthritis Market

 

Psoriatic arthritis (PsA) Market Outlook

Psoriatic arthritis (PsA) market outlook builds a detailed comprehension of the historical, current, and forecasted psoriatic arthritis (PsA) market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

 

This segment gives a thorough detail of psoriatic arthritis (PsA) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and KOL view. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

As per DelveInsight, psoriatic arthritis (PsA) market in 7MM is expected to change in the study period 2019–2032.

 

Key Findings

This section includes a glimpse of psoriatic arthritis (PsA) market in 7MM. In the 7MM, psoriatic arthritis (PsA) market size was approximately USD 9 billion in 2021.

 

The United States: Psoriatic Arthritis Market Outlook

This section provides the total psoriatic arthritis (PsA) market size. It also provides the market size of psoriatic arthritis (PsA) by systemic therapies and by-products in the United States.

 

The United States accounts for the highest market size of psoriatic arthritis (PsA) than the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

 

EU-5 Countries: Psoriatic Arthritis Market Outlook

This section provides the total psoriatic arthritis (PsA) market size. It also provides the market size of psoriatic arthritis (PsA) by systemic therapies and by-products in Germany, France, Italy, Spain, and the United Kingdom.

 

Japan: Psoriatic Arthritis Market Outlook

This section provides the total psoriatic arthritis (PsA) market size. It also provides the market size of psoriatic arthritis (PsA) by systemic therapies and by-products in Japan.

 

‘Psoriatic Arthritis Market Outlook

 

Psoriatic Arthritis (PsA) Drugs Uptake

This section focuses on the uptake rate of potential drugs recently launched or expected to get launched in the market during the study period 2019–2032. The analysis covers psoriatic arthritis (PsA) market uptake by drugs, patient uptake by therapies, and sales of each drug.

 

This helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Psoriatic Arthritis (PsA) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stages. It also analyses psoriatic arthritis (PsA)’s key players in developing targeted therapeutics.

 

Major players include Sun Pharmaceuticals, Bristol Myers Squibb, Affibody AB, UCB Biopharma and others whose key products are expected to get launched in the US market by 20XX.

 

Pipeline Development Activities

The report covers information on collaborations, acquisitions, mergers, licensing, and patent details for emerging psoriatic arthritis (PsA) therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in psoriatic arthritis (PsA) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or psoriatic arthritis (PsA) market trends. This will support the clients in potential novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a competitive and market intelligence analysis of psoriatic arthritis (PsA) market using various competitive intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

 

Report Metrics

Details

Study Period

2019 to 2032

Base Year

2021

Forecast Period

2022 to 2032

CAGR

Request Sample to Know

Market Size

USD 9 Billion in 2021

Key Companies

UCB Biopharma, Sun Pharmaceutical Industries Limited, BMS, Affibody AB, Janssen Biotech, Amgen, Eli Lilly and Company, AbbVie, Pfizer

Scope of the Report

  • The report covers the descriptive overview of psoriatic arthritis (PsA), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight is provided into psoriatic arthritis (PsA) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for psoriatic arthritis (PsA) is provided, along with the assessment of new therapies that will impact the current treatment landscape
  • A detailed review of psoriatic arthritis (PsA) market; historical and forecasted, is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global psoriatic arthritis (PsA) market

Report Highlights

  • Recently, psoriatic arthritis (PsA) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence psoriatic arthritis (PsA) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for psoriatic arthritis (PsA). The launch of emerging therapies will significantly impact psoriatic arthritis (PsA) market
  • For psoriatic arthritis (PsA), a better understanding of disease pathogenesis will also contribute to developing novel therapeutics
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the R&D activities

Psoriatic Arthritis (PsA) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Psoriatic Arthritis (PsA) Pipeline Analysis
  • Psoriatic Arthritis (PsA) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Psoriatic Arthritis (PsA) Report Key Strengths

  • 11-year Forecast
  • 7MM Coverage
  • Psoriatic Arthritis (PsA) Epidemiology Segmentation
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake

Psoriatic Arthritis (PsA) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness

Key Questions

Market Insights:

  • What was the market share percentage distribution, and how would it look by 2032?
  • What would be the total market size and market size of psoriatic arthritis (PsA) by therapies across the 7MM forecast period (2019–2032)?
  • What are the key findings about the market across 7MM, and which country will have the largest psoriatic arthritis (PsA) market size during the forecast period (2019–2032)?
  • At what CAGR is psoriatic arthritis (PsA) market expected to grow in the 7MM forecast period (2019–2032)?
  • What would be psoriatic arthritis (PsA) market outlook across the 7MM forecast period (2019–2032)?
  • What would be psoriatic arthritis (PsA) market growth until 2032 and the resultant market size by 2032?
  • How would future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of psoriatic arthritis (PsA)?
  • What is the historical patient pool of psoriatic arthritis (PsA) covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of psoriatic arthritis (PsA) covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population of psoriatic arthritis (PsA)?
  • Out of all the 7MM, which country would have the highest prevalence of psoriatic arthritis (PsA) during the forecast period (2019–2032)?
  • At what CAGR is the population expected to grow in the 7MM during the forecast period (2019–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options to treat psoriatic arthritis (PsA)?
  • What are the current treatment guidelines for treating psoriatic arthritis (PsA) in the US, Europe, and Japan?
  • What are psoriatic arthritis (PsA) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies to treat psoriatic arthritis (PsA)?
  • How many therapies are developed by each company to treat psoriatic arthritis (PsA)?
  • How many emerging therapies are in the mid-stage and late stages of development to treat psoriatic arthritis (PsA)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to psoriatic arthritis (PsA) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies for psoriatic arthritis (PsA) and its status?
  • Which key designations have been granted for the emerging therapies for psoriatic arthritis (PsA)?
  • What are the global historical and forecasted psoriatic arthritis (PsA) markets?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving psoriatic arthritis (PsA) market
  • To understand the future market competition in psoriatic arthritis (PsA) market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for psoriatic arthritis (PsA) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identifying upcoming solid players in the market will help devise strategies that will help get ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for psoriatic arthritis (PsA) market
  • To understand the future market competition in psoriatic arthritis (PsA) market

Frequently Asked Questions

What is Psoriatic Arthritis?
Psoriatic arthritis is a type of arthritis that occurs in certain persons who have psoriasis, a disease that creates red patches of skin covered in silvery scales. Most people get psoriasis years before they get psoriatic arthritis.
What is the Psoriatic Arthritis Market Size in 7MM?
The total Psoriatic Arthritis market size was accounted for USD 9 Billion in the year 2021 and is estimated to grow during the study period (2019-2032).
Who are the leading companies in the Psoriatic Arthritis Market Landscape?
The key players in the Psoriatic Arthritis market who are in different phases of developing Obesity Therapies are - AbbVie, Amgen, Johnson & Johnson, Bristol, Myers Squibb Company, Celgene Corporation, Novartis, Eli Lilly and Company, and UCB Biosciences Inc., and others.
What are the Key strengths of the Psoriatic Arthritis Market Report?
Key strengths of the Psoriatic Arthritis Market Report are 11 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Market Size, Drug Uptake, Pipeline Therapies, Market Drivers and Market Barriers, and upcoming Psoriatic Arthritis market trends.
Which country is expected to account for the most significant prevalent cases for Psoriatic Arthritis in the 7MM?
The United States is expected to account for the highest prevalent Psoriatic Arthritis cases.

1. Key Insights

2. Report Introduction

3. Psoriatic Arthritis Market Overview at a Glance

3.1. Market Share (%) Distribution of PsA in 2019

3.2. Market Share (%) Distribution of PsA in 2032

4. Executive Summary of Psoriatic Arthritis

5. Disease Background and Overview

5.1. Introduction

5.2. Clinical Manifestations

5.3. Classification

5.4. Risk Factors

5.5. Pathogenesis

5.6. Diagnosis

5.7. Differential Diagnosis

5.8. Treatment and Management

5.8.1. ACR/NPF Recommendations for PsA

5.8.2. Summary of differences in recommendations

5.8.3. EULAR Recommendations

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Total Prevalence of PsA in the 7MM

6.3. Assumption and Rationale

6.4. The United States

6.4.1. Prevalent cases of PsA in the United States

6.4.2. Diagnosed Cases of PsA in the United States

6.4.3. Gender-specific Cases of PsA in the United States

6.4.4. Age-specific Cases of PsA in the United States

6.4.5. Severity-specific Cases of PsA in the United States

6.5. EU5

6.5.1. Total Prevalent Cases of PsA in the EU5

6.5.2. Germany

6.5.2.1. Diagnosed Cases of PsA in Germany

6.5.2.2. Gender-specific Cases of PsA in Germany

6.5.2.3. Age-specific Cases of PsA in Germany

6.5.2.4. Severity-specific Cases of PsA in Germany

6.5.3. France

6.5.3.1. Diagnosed Cases of PsA in France

6.5.3.2. Gender-specific Cases of PsA in France

6.5.3.3. Age-specific Cases of PsA in France

6.5.3.4. Severity-specific Cases of PsA in France

6.5.4. Italy

6.5.4.1. Diagnosed Cases of PsA in Italy

6.5.4.2. Gender-specific Cases of PsA in Italy

6.5.4.3. Age-specific Cases of PsA in Italy

6.5.4.4. Severity-specific Cases of PsA in Italy

6.5.5. Spain

6.5.5.1. Diagnosed Cases of PsA in Spain

6.5.5.2. Gender-specific Cases of PsA in Spain

6.5.5.3. Age-specific Cases of PsA in Spain

6.5.5.4. Severity-specific Cases of PsA in Spain

6.5.6. The United Kingdom

6.5.6.1. Diagnosed Cases of PsA in the UK

6.5.6.2. Gender-specific Cases of PsA in the UK

6.5.6.3. Age-specific Cases of PsA in the UK

6.5.6.4. Severity-specific Cases of PsA in the UK

6.6. Japan

6.6.1. Prevalent cases of PsA in Japan

6.6.2. Diagnosed Cases of PsA in Japan

6.6.3. Gender-specific Cases of PsA in Japan

6.6.4. Age-specific Cases of PsA in Japan

6.6.5. Severity-specific Cases of PsA in Japan

7. Patient Journey of Psoriatic Arthritis

8. Marketed Products

8.1. Key Cross: Marketed Products

8.2. TREMFYA (guselkumab): Janssen Biotech

8.2.1. Product description

8.2.2. Regulatory milestones

8.2.3. Other development activities

8.2.4. Safety and efficacy of TREMFYA

8.2.5. Side effects of TREMFYA

8.2.6. Product profile

8.3. OTEZLA (apremilast): Amgen

8.3.1. Product description

8.3.2. Regulatory milestones

8.3.3. Other development activities

8.3.4. Safety and efficacy of OTEZLA

8.3.5. Side effects of OTEZLA

8.3.6. Product profile

8.4. SIMPONI (golimumab): Janssen Biotech

8.4.1. Product description

8.4.2. Regulatory milestones

8.4.3. Other development activities

8.4.4. Safety and efficacy of SIMPONI

8.4.5. Product profile

8.5. CIMZIA (certolizumab): UCB Pharma

8.5.1. Product description

8.5.2. Regulatory milestones

8.5.3. Other development activities

8.5.4. Safety and efficacy of CIMZIA

8.5.5. Side effects of CIMZIA

8.5.6. Product profile

8.6. ORENCIA (abatacept): Bristol-Myers Squibb

8.6.1. Product description

8.6.2. Regulatory milestones

8.6.3. Other development activities

8.6.4. Safety and efficacy of ORENCIA

8.6.5. Side effects of ORENCIA

8.6.6. Product profile

8.7. TALTZ (ixekizumab): Eli Lilly and Company

8.7.1. Product description

8.7.2. Regulatory milestones

8.7.3. Other development activities

8.7.4. Safety and efficacy of TALTZ

8.7.5. Side effects of TALTZ

8.7.6. Product profile

8.8. REMICADE (infliximab): Janssen Biotech

8.8.1. Product description

8.8.2. Regulatory milestones

8.8.3. Other development activities

8.8.4. Safety and efficacy of REMICADE

8.8.5. Side effects of REMICADE

8.8.6. Product profile

8.9. SKYRIZI (risankizumab): AbbVie

8.9.1. Product description

8.9.2. Regulatory milestone

8.9.3. Other development activities

8.9.4. Safety and efficacy of SKYRIZI

8.9.5. Product profile

8.10. HUMIRA (adalimumab): AbbVie

8.10.1. Product description

8.10.2. Regulatory milestone

8.10.3. Other development activities

8.10.4. Safety and efficacy of HUMIRA

8.10.5. Side effects of HUMIRA

8.10.6. Product profile

8.11. RINVOQ (upadacitinib): AbbVie

8.11.1. Product description

8.11.2. Regulatory milestone

8.11.3. Safety and efficacy of RINVOQ

8.11.4. Product profile

8.12. ENBREL (etanercept): Amgen

8.12.1. Product description

8.12.2. Regulatory milestone

8.12.3. Other development activities

8.12.4. Safety and efficacy of ENBREL

8.12.5. Side effects of ENBREL

8.12.6. Product profile

8.13. XELJANZ (tofacitinib): Pfizer

8.13.1. Product description

8.13.2. Regulatory milestone

8.13.3. Safety and efficacy of XELJANZ

8.13.4. Side effects of XELJANZ

8.13.5. Product profile

8.14. STELARA (ustekimumab): Janssen Biotech

8.14.1. Product description

8.14.2. Regulatory milestone

8.14.3. Other development activities

8.14.4. Safety and efficacy of STELARA

8.14.5. Side effects of STELARA

8.14.6. Product profile

9. Emerging Therapies

9.1. Key cross: Emerging

9.2. Bimekizumab: UCB Biopharma

9.2.1. Drug description

9.2.2. Other development activities

9.2.3. Clinical development

9.2.4. Clinical trial information

9.2.5. Safety and efficacy

9.2.6. Product profile

9.2.7. Analyst Comment

9.3. Tildrakizumab: Sun Pharmaceutical Industries Limited

9.3.1. Drug description

9.3.2. Other development activities

9.3.3. Clinical development

9.3.4. Clinical trial information

9.3.5. Safety and efficacy

9.3.6. Product profile

9.3.7. Analyst Comment

9.4. Deucravacitinib: BMS

9.4.1. Drug description

9.4.2. Clinical development

9.4.3. Clinical trial information

9.4.4. Safety and efficacy

9.4.5. Product profile

9.4.6. Analyst Comment

9.5. Izokibep: Affibody AB

9.5.1. Drug description

9.5.2. Other development activities

9.5.3. Clinical development

9.5.4. Clinical trial information

9.5.5. Safety and efficacy

9.5.6. Product profile

9.5.7. Analyst Comment

10. Other Assets

10.1. Key cross: Other assets

10.2. NDI-034858: Nimbus Therapeutics

10.2.1. Drug description

10.2.2. Clinical development

10.2.3. Clinical trial information

10.2.4. Product profile

10.3. Neihulizumab: AltruBio

10.3.1. Drug description

10.3.2. Clinical development

10.3.3. Clinical trial information

10.3.4. Safety and efficacy

10.3.5. Product profile

11. Psoriatic Arthritis (PsA): Seven Major Market Analysis

11.1. Key Findings

11.2. Total Market Size of PsA in the 7MM

11.3. Market Outlook

11.4. Biosimilars

11.5. Attribute Analysis

11.6. The United States Market Size

11.6.1. Total Market Size of PsA in the United States

11.6.2. Market Size of PsA by Systemic Therapies in the United States

11.6.3. Market Size of PsA by Product

11.7. The EU-5 Market Size

11.7.1. Total Market Size of PsA in the EU-5

11.7.2. Germany

11.7.2.1. Market Size of PsA in Germany by Systemic Therapies

11.7.2.2. Market Size of PsA in Germany by Products

11.7.3. France

11.7.3.1. Market Size of PsA in France by Systemic Therapies

11.7.3.2. Market Size of PsA in France by Products

11.7.4. Italy

11.7.4.1. Market Size of PsA in Italy by Systemic Therapies

11.7.4.2. Market Size of PsA in Italy by Products

11.7.5. Spain

11.7.5.1. Market Size of PsA in Spain by Systemic Therapies

11.7.5.2. Market Size of PsA in Spain by Products

11.7.6. The United Kingdom

11.7.6.1. Market Size of PsA in the UK by Systemic Therapies

11.7.6.2. Market Size of PsA in the United Kingdom by Products

11.8. Japan Market Size

11.8.1.1. Total Market Size of PsA in Japan

11.8.1.2. Market Size of PsA in Japan by Systemic Therapies

11.8.1.3. Market Size of PsA in Japan by Products

12. SWOT Analysis

13. KOL Views

14. Unmet Needs

15. Market Access

16. Acronyms and Abbreviations

17. Appendix

17.1. Bibliography

17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Table

Table 1: Summary of PsA, Epidemiology, and Key Events (2019–2032)

Table 2: Role of HLA Genes in PsA

Table 3: Role of non-HLA Genes in PsA

Table 4: CASPAR Criteria

Table 5: Moll and Wright Classification

Table 6: Operational Definition of Classification of PsA

Table 7: Suggested Diagnostic Algorithm

Table 8: Clinical Characteristics of Different Types of Arthritis That can aid Differential Diagnosis

Table 9: 2018 ACR/NPF Recommendations for the Initial Treatment for Active PsA who are OSM‐ and Other Treatment-naive

Table 10: 2018 ACR/NPF Recommendations for Active PsA Despite Treatment With a TNFi Biologics

Table 11: 2018 ACR/NPF Recommendations for Active PsA Despite Treatment With an IL‐17i or an IL‐12/23i Biologics

Table 12: 2018 ACR/NPF Recommendations for PsA Including Treat‐to‐target, Active Axial Disease, Enthesitis, or Active IBD

Table 13: 2018 ACR/NPF Recommendations for PsA and Comorbidities, Including Concomitant Diabetes and Recurrent Serious Infections

Table 14: 2018 ACR/NPF Recommendations for Non-pharmacologic Interventions in Patients With Active PsA Regardless of Pharmacologic Treatment Status

Table 15: Summary of Differences in Recommendations

Table 16: 2019 EULAR Overarching Principles

Table 17: 2019 EULAR Recommendations for the Pharmacological Management of PsA

Table 18: Total Prevalent Cases of PsA in the 7MM (2019–2032)

Table 19: Prevalent cases of PsA in the United States (2019–2032)

Table 20: Diagnosed Cases of PsA in the United States (2019–2032)

Table 21: Gender-specific Cases of PsA in the United States (2019–2032)

Table 22: Age-specific Cases of PsA in the United States (2019–2032)

Table 23: Severity-specific cases of PsA in the United States (2019–2032)

Table 24: Prevalent Cases of PsA in the EU5 (2019–2032)

Table 25: Diagnosed cases of PsA in Germany (2019–2032)

Table 26: Gender-specific Cases of PsA in Germany (2019–2032)

Table 27: Age-specific Cases of PsA in Germany (2019–2032)

Table 28: Severity-specific cases of PsA in Germany (2019–2032)

Table 29: Diagnosed cases of PsA in France (2019–2032)

Table 30: Gender-specific Cases of PsA in France (2019–2032)

Table 31: Age-specific Cases of PsA in France (2019–2032)

Table 32: Severity-specific cases of PsA in France (2019–2032)

Table 33: Diagnosed cases of PsA in Italy (2019–2032)

Table 34: Gender-specific Cases of PsA in Italy (2019–2032)

Table 35: Age-specific Cases of PsA in Italy (2019–2032)

Table 36: Severity-specific cases of PsA in Italy (2019–2032)

Table 37: Diagnosed cases of PsA in Spain (2019–2032)

Table 38: Gender-specific Cases of PsA in Spain (2019–2032)

Table 39: Age-specific Cases of PsA in Spain (2019–2032)

Table 40: Severity-specific cases of PsA in Spain (2019–2032)

Table 41: Diagnosed cases of PsA in the UK (2019–2032)

Table 42: Gender-specific Cases of PsA in the UK (2019–2032)

Table 43: Age-specific Cases of PsA in the UK (2019–2032)

Table 44: Severity-specific cases of PsA in the UK (2019–2032)

Table 45: Prevalent cases of PsA in Japan (2019–2032)

Table 46: Diagnosed Cases of PsA in Japan (2019–2032)

Table 47: Gender-specific Cases of PsA in Japan (2019–2032)

Table 48: Age-specific Cases of PsA in Japan (2019–2032)

Table 49: Severity-specific cases of PsA in Japan (2019–2032)

Table 50: Key cross of marketed products

Table 51: Key cross of emerging drugs

Table 52: Bimekizumab, Clinical Trial Description, 2022

Table 53: Tildrakizumab, Clinical Trial Description, 2022

Table 54: Deucravacitinib, Clinical Trial Description, 2022

Table 55: Tildrakizumab, Clinical Trial Description, 2022

Table 56: Key cross of emerging drugs

Table 57: NDI-034858, Clinical Trial Description, 2022

Table 58: Neihulizumab, Clinical Trial Description, 2022

Table 59: Total Market Size of PsA in the 7MM in USD Million (2019–2032)

Table 60: FDA Approved Biosimilars for PsA

Table 61: Biosimilars in Development

Table 62: Weighted Score Based on Ranking

Table 63: Market Size of PsA in the United States in USD Million (2019–2032)

Table 64: Market Size of PsA in the United State by Systemic Therapies in USD Million (2019–2032)

Table 65: Market Size of PsA in the United State by Products in USD Million (2019–2032)

Table 66: The EU5 Market Size of PsA in USD Million (2019–2032)

Table 67: Market Size of PsA in Germany by Systemic Therapies in USD Million (2019–2032)

Table 68: Market Size of PsA in Germany by Products in USD Million (2019–2032)

Table 69: Market Size of PsA in France by Systemic Therapies in USD Million (2019–2032)

Table 70: Market Size of PsA in France by Products in USD Million (2019–2032)

Table 71: Market Size of PsA in Italy by Systemic Therapies in USD Million (2019–2032)

Table 72: Market Size of PsA in Italy by Products in USD Million (2019–2032)

Table 73: Market Size of PsA in Spain by Systemic Therapies in USD Million (2019–2032)

Table 74: Market Size of PsA in Spain by Products in USD Million (2019–2032)

Table 75: Market Size of PsA in the UK by Systemic Therapies in USD Million (2019–2032)

Table 76: Market Size of PsA in the UK by Products in USD Million (2019–2032)

Table 77: Total Market Size of PsA in Japan in USD Million (2019–2032)

Table 78: Market Size of PsA in Japan by Systemic Therapies in USD Million (2019–2032)

Table 79: Market Size of PsA in Japan by Products in USD Million (2019–2032)

List of Figures

Figure 1: Clinical Presentations of PsA

Figure 2: Classification of PsA

Figure 3: Risk Factors

Figure 4: Role of Obesity and Risk of Cardiovascular Comorbidities in PsA patients

Figure 5: Key cell Types and Secretion of key Inflammatory Mediators in PsA

Figure 6: Adaptive and Innate Immune Cells and Activated Pathways in PsA

Figure 7: Diagnosis of PsA

Figure 8: Radiographic Features of PsA

Figure 9: Differential Diagnosis

Figure 10: Pharmacologic, Non-pharmacologic, and Symptomatic Therapies for PsA

Figure 11: The EULAR 2019 Algorithm for Treatment of PsA With Pharmacological Non-topical Treatments

Figure 12: PsA Treatment Pathway Following Inadequate Response to DMARDs (NICE)

Figure 13: Total Prevalent Cases of PsA in the 7MM (2019–2032)

Figure 14: Prevalent cases of PsA in the United States (2019–2032)

Figure 15: Diagnosed Cases of PsA in the United States (2019–2032)

Figure 16: Gender-specific cases of PsA in the United States (2019–2032)

Figure 17: Age-specific Cases of PsA in the United States (2019–2032)

Figure 18: Severity-specific Cases of PsA in the United States (2019–2032)

Figure 19: Prevalent Cases of PsA in the EU5 (2019–2032)

Figure 20: Diagnosed cases of PsA in Germany (2019–2032)

Figure 21: Gender-specific cases of PsA in Germany (2019–2032)

Figure 22: Age-specific Cases of PsA in Germany (2019–2032)

Figure 23: Severity-specific Cases of PsA in Germany (2019–2032)

Figure 24: Diagnosed cases of PsA in France (2019–2032)

Figure 25: Gender-specific cases of PsA in France (2019–2032)

Figure 26: Age-specific Cases of PsA in France (2019–2032)

Figure 27: Severity-specific Cases of PsA in France (2019–2032)

Figure 28: Diagnosed cases of PsA in Italy (2019–2032)

Figure 29: Gender-specific cases of PsA in Italy (2019–2032)

Figure 30: Age-specific Cases of PsA in Italy (2019–2032)

Figure 31: Severity-specific Cases of PsA in Italy (2019–2032)

Figure 32: Diagnosed cases of PsA in Spain (2019–2032)

Figure 33: Gender-specific cases of PsA in Spain (2019–2032)

Figure 34: Age-specific Cases of PsA in Spain (2019–2032)

Figure 35: Severity-specific Cases of PsA in Spain (2019–2032)

Figure 36: Diagnosed cases of PsA in the UK (2019–2032)

Figure 37: Gender-specific cases of PsA in the UK (2019–2032)

Figure 38: Age-specific Cases of PsA in the UK (2019–2032)

Figure 39: Severity-specific Cases of PsA in the UK (2019–2032)

Figure 40: Prevalent cases of PsA in Japan (2019–2032)

Figure 41: Diagnosed Cases of PsA in Japan in thousands (2019–2032)

Figure 42: Gender-specific cases of PsA in Japan (2019–2032)

Figure 43: Age-specific Cases of PsA in Japan (2019–2032)

Figure 44: Severity-specific Cases of PsA in Japan (2019–2032)

Figure 45: Total Market Size of PsA in the 7MM (2019–2032)

Figure 46: Market Size of PsA in the United States (2019–2032)

Figure 47: Market Size of PsA in the United States by Systemic Therapies (2019–2032)

Figure 48: Market Size of PsA in the United States by Products (2019–2032)

Figure 49: The EU5 Market Size of PsA (2019–2032)

Figure 50: Market Size of PsA in Germany by Systemic Therapies (2019–2032)

Figure 51: Market Size of PsA in Germany by Products (2019–2032)

Figure 52: Market Size of PsA in France by Systemic Therapies (2019–2032)

Figure 53: Market Size of PsA in France by Products (2019–2032)

Figure 54: Market Size of PsA in Italy by Systemic Therapies (2019–2032)

Figure 55: Market Size of PsA in Italy by Products (2019–2032)

Figure 56: Market Size of PsA in Spain by Systemic Therapies (2019–2032)

Figure 57: Market Size of PsA in Spain by Products (2019–2032)

Figure 58: Market Size of PsA in the UK by Systemic Therapies (2019–2032)

Figure 59: Market Size of PsA in the UK by Products (2019–2032)

Figure 60: Total Market Size of PsA in Japan (2019–2032)

Figure 61: Market Size of PsA in Japan by Systemic Therapies in USD Million (2019–2032)

Figure 62: Market Size of PsA in Japan by Products (2019–2032)

UCB Biopharma
Sun Pharmaceutical Industries Limited
BMS
Affibody AB
Janssen Biotech
Amgen
Eli Lilly and Company
AbbVie
Pfizer

 

Forward to Friend

Need A Quote